Cargando…
Fulvestrant-3-Boronic Acid (ZB716) Demonstrates Oral Bioavailability and Favorable Pharmacokinetic Profile in Preclinical ADME Studies
Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to have high plasma protein binding in human and animal plasma,...
Autores principales: | Liu, Jiawang, Rajasekaran, Nirmal, Hossain, Ahamed, Zhang, Changde, Guo, Shanchun, Kang, Borui, Jung, Hunsoon, Kim, Hongjoong, Wang, Guangdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400955/ https://www.ncbi.nlm.nih.gov/pubmed/34451816 http://dx.doi.org/10.3390/ph14080719 |
Ejemplares similares
-
Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
por: Zhang, Changde, et al.
Publicado: (2017) -
ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models
por: Guo, Shanchun, et al.
Publicado: (2018) -
Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability
por: Zhang, Changde, et al.
Publicado: (2019) -
SAT-341 Pharmacology and Metabolism of GLL398 an Oral Selective Estrogen Receptor Degrader for Endocrine Therapy of Breast Cancer
por: Guo, Shanchun, et al.
Publicado: (2019) -
Design, Synthesis, and Evaluation of Niclosamide Analogs as Therapeutic Agents for Enzalutamide-Resistant Prostate Cancer
por: Kang, Borui, et al.
Publicado: (2023)